

Project Details	
Project Code	MRCIIAR26Ca Serpi
Title	Stop “Superbugs” to fight antimicrobial resistance
Research Theme	IIAR
Project Type	Wet lab
Summary	While antibiotics have revolutionised the landscape of medicine saving millions of lives, their misuse has also resulted in the rise of “Superbugs”, which are bacteria resistant to most of the standard antibiotics. The continuing rise of antimicrobial resistance has led to the failure of antibiotics to treat common infections. This project proposes to develop novel antimicrobials that target bacterial cell division, a crucial step for bacterial replication and survival. We will combine our expertise in medicinal chemistry and microbiology to design molecules that, acting like “Trojan horses”, cross the bacterial cell envelope and once inside become toxic and kill bacteria.
Description	<p>Background: Despite antibiotics crucial role in saving millions of lives, they have proven to become significantly less effective in treating common infections due to the spread of Antimicrobial Resistance (AMR) worldwide. Now more than ever, it is imperative to develop novel anti-bacterial drugs and to identify novel targets to fight the widespread emergence of bacterial pathogens resistant to current therapeutic options. Among the most promising targets for the discovery of novel classes of broad-spectrum antimicrobials is the bacterial cell division, a process orchestrated by the filamenting temperature-sensitive mutant Z (FtsZ) protein, an enzyme identified as essential for bacterial growth. Due to its essential role in bacterial division and wide conservation across bacteria species, FtsZ is an appealing drug target. A growing number of small molecules have been reported to interact with FtsZ and to affect bacterial cell division. Among them a difluoro-benzamide derivative (PC190723) served to validate FtsZ as an antibacterial target as it was shown to effectively inhibits bacterial cell division, to have in vitro bactericidal activity against staphylococci, including methicillin- and MDR resistant <i>Staphylococcus aureus</i> and to protect mice from a lethal dose of <i>S. aureus</i>. Effective inhibition of FtsZ stops cell division, triggers cell enlargement and subsequent lysis, leading to bacteria death, indicating that FtsZ is a suitable target for antibiotic discovery. Two binding sites can be exploited for the design of FtsZ inhibitors: the interdomain (beneath the H7 helix and adjacent to the T7 loop) and the GTP binding sites. Although, many inhibitors at the interdomain site have been reported only one made into the clinic (TX0709), possibly due to their unsuitable pharmacological properties and a relatively high frequency of resistance mutations. This site also shows limited conservation across bacterial species posing a challenge in the design of broad-spectrum antimicrobials. FtsZ guanosine triphosphate (GTP) binding site is widely conserved throughout the bacterial species and no drug resistant GTP binding site mutants have been reported so far, presumably because it is essential for the GTP correct recognition. GTP analogues with small hydrophobic substituents at C8 of the nucleobase have been reported to efficiently inhibit FtsZ polymerization and GTPase activity, without inhibiting its eukaryotic homologue tubulin, likely due</p>

	<p>to their low sequence similarity. Although potent and selective FtsZ inhibitors, these compounds were devoid of antibacterial activity as they could not pass the bacterial cell envelope, which is practically impermeable for the highly polar, negatively charged phosphates group of the nucleotides.</p> <p>Key research question. Could nucleotide FtsZ inhibitors be developed as antibiotics to fight AMR? One major challenge in antibiotic drug discovery is indeed to develop molecules able to rapidly penetrate the bacterial cell envelope to achieve a lethal intracellular drug accumulation. To enable nucleotide FtsZ inhibitors to cross the bacterial cell envelope, we propose to temporarily block the free phosphonic functional group of the molecule, masking its acidic oxygen atoms with metabolically labile and non-toxic protecting groups to produce a charge-neutral compound (prodrug). Such prodrugs with increased lipophilicity, will cross the bacterial cell wall and once inside upon activation will release the antimicrobial drug. As an additional advantage these prodrugs having one or more phosphate groups attached to the nucleoside, do not require all the phosphorylation steps decreasing the chance for the bacteria to become resistance through mutation of the phosphorylating enzymes. Phosphate prodrug approaches have been successfully applied to antiviral and anticancer nucleoside analogues with many of these drugs reaching the clinic. It is extremely important to establish if such powerful technologies have the potential to lead to novel therapeutics to fight AMR.</p> <p>Objective 1 is the design and synthesis of prodrugs masking only the last phosphate group while keeping the others partially charged to stabilize the anhydride bonds. The student will investigate prodrugs, whose intracellular cleavage is based on an entirely pH-driven chemical hydrolysis or enzymatic activation processes. They will also optimize the nucleoside scaffold using in silico studies to identify more potent inhibitors.</p> <p>Objective 2 is the prodrugs chemical and enzymatic stability and their activation study by bacterial enzymes using HPLC to determine the half-lives and LCMS to identify metabolites.</p> <p>Objective 3 is the evaluation of the in vitro prodrugs antibacterial, antibiofilm activity in planktonic culture as well as biofilm of multiple isolates of multi drug resistant bacteria and toxicity in human cell lines. We will examine cell division using fluorescence microscopy in FtsZ green fluorescent protein labelled bacteria.</p> <p>Objective 4 is the study on the bacterial response to the novel prodrugs to establish if they can escape pre-existing resistance mechanisms. We will examine phenotypic responses to prodrugs, conducting real-time diffusion-mutation assays and microfluidic single-cell experiments.</p> <p>In summary this research will generate new knowledge, insight and novel antibacterial molecules which will contribute to counteract the continuing emergence and spread of AMR.</p>
Supervisory Team	
Lead Supervisor	
Name	Dr Michaela Serpi
Affiliation	Cardiff

College/Faculty	College of Physical Sciences and Engineering
Department/School	School of Chemistry
Email Address	serpim5@cardiff.ac.uk
Co-Supervisor 1	
Name	Dr Maisem Laabei
Affiliation	Bristol
College/Faculty	Faculty of Life Sciences
Department/School	School of Cellular and Molecular Medicine
Co-Supervisor 2	
Name	Dr Tobias Bergmiller
Affiliation	Exeter
College/Faculty	Biosciences
Department/School	Living Systems Institute
Co-Supervisor 3	
Name	Professor Ian Fallis
Affiliation	Cardiff
College/Faculty	College of Physical Sciences and Engineering
Department/School	School of Chemistry